Immunic (IMUX) Fundamentals 2026 — Revenue Analysis | SniperIQ
Immunic (IMUX) is a US-listed Healthcare company in Biotechnology with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Immunic's market cap?
Immunic (IMUX) has a market capitalization of approximately
What is Immunic's P/E ratio?
Immunic's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Immunic?
Immunic runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does Immunic pay a dividend?
Immunic does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Immunic financially healthy?
Immunic carries a debt-to-equity ratio of 0.00x and a current ratio of 4.92x, with a market beta of 1.38. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Immunic a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Immunic (IMUX) the key facts are: market cap
Track Immunic's full fundamentals live
Get Immunic's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.